SightfileU.S. market data from official filings

Companies › REGN

REGENERON PHARMACEUTICAL (REGN)

Institutional ownership, SEC filings and insider activity

Sector: Healthcare & Pharma · SEC CIK 0000872589 · EDGAR filings · Updated 2026-07-07

REGENERON PHARMACEUTICAL (REGN) has reported institutional ownership of 84.4%, with 1,384 institutional managers holding positions valued at $67.7B per the latest 13F reporting period.

Institutional ownership
84.4%
Institutional managers
1,384
Reported 13F value
$67.7B
Insider activity
104 trans.
−$9.32M net selling

Latest updates

Institutional ownership overview

According to SEC 13F filings tracked by Sightfile, REGENERON PHARMACEUTICAL has 1,384 institutional holders and institutional ownership of 84.4%.

#InstitutionReported value% of tracked total
1BlackRock, Inc.$6.91B10.2%
2VANGUARD CAPITAL MANAGEMENT LLC$5.14B7.6%
3STATE STREET CORP$3.60B5.3%
4Dodge & Cox$3.44B5.1%
5JPMORGAN CHASE & CO$3.23B4.8%
6FRANKLIN RESOURCES INC$2.10B3.1%
7GEODE CAPITAL MANAGEMENT, LLC$2.01B3.0%
8PRICE T ROWE ASSOCIATES INC /MD/$1.68B2.5%
9Nuveen, LLC$1.60B2.4%
10LOOMIS SAYLES & CO L P$1.48B2.2%

Full holder history and quarter-over-quarter changes are available inside the app.

Insider activity

Insiders reported 104 transactions (0 buys, 57 sells) across 19 reporting insiders, with a net reported value of −$9.32M.

Related companies

BRISTOL-MYERS SQUIBB CO (BMY) · MEDTRONIC PLC (MDT) · BOSTON SCIENTIFIC CORP (BSX) · HCA HEALTHCARE INC (HCA) · 3M CO (MMM) · ZOETIS INC (ZTS)

See full history, cross-references and alerts on Sightfile
Sightfile provides information only — not investment advice, recommendations, or an assessment of any security. Data is derived from official public sources (SEC EDGAR and U.S. government agencies), may contain errors or delays, and should be verified against the source filing before relying on it.
Data sources: SEC EDGAR (filings, 13F, FTD), aggregated by Sightfile. Page updated 2026-07-07.